Ideaya Biosciences received FDA IND clearance to begin a Phase I study of IDE‑034, a bispecific antibody‑drug conjugate targeting B7H3/PTK7 coupled to a TOP1 payload, in patients with advanced solid tumors. The clearance enables dose‑escalation testing of the conjugate to define safety, pharmacokinetics and preliminary antitumor activity. IDE‑034 joins a growing wave of bispecific and targeted payload conjugates designed to increase tumor specificity while limiting off‑target toxicity. Ideaya framed the IND as a step toward demonstrating the conjugate’s tolerability and potential activity in hard‑to‑treat solid tumors where B7H3 and PTK7 are overexpressed. The program’s progress will be watched for early signals of tumor penetration, bystander effects and combinability with immune modulators, which are common development pathways for next‑generation ADCs.